research Evaluation of an eucalyptus oil containing topical drug delivery system for selected steroid hormones
The eucalyptus oil system improved skin delivery of hormones, but safety concerns remain.
Search
for
Sort by
Research
240-270 / 1000+ results
research Topical use of systemic drugs in dermatology: A comprehensive review
Using systemic drugs as creams for skin conditions shows promise, but more research is needed to confirm their effectiveness and safety.
research A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
research MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children
Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research LB1048 Effectiveness of OR-101 in a murine model of atopic dermatitis
OR101 may effectively treat atopic dermatitis and similar skin conditions.
research The Comparative Potency of Hydrocortisone Analogs in Suppressing Growth of Hair in the Rat121From the Departments of Dermatology and Syphilology and of Anatomy, University of Michigan Medical School, Ann Arbor, Michigan.2Supported in part by research grants from the National Institutes of Health, United States Public Health Service (A-131 (C5)), the University of Michigan Memorial-Phoenix Project #145 and The Upjohn Company.
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
research Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata (AA)
Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
research Methotrexate for induction of remission in ulcerative colitis
Methotrexate is not proven effective for inducing remission in ulcerative colitis.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research The Acute Anticonvulsant Effects of Deoxycorticosterone in Developing Rats: Role of Metabolites and Mineralocorticoid‐receptor Responses
Deoxycorticosterone and its metabolites help prevent seizures by interacting with specific receptors.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Cedrol mitigates hepatic lipid accumulation and adipocyte hypertrophy induced by corticosteroids through the inhibition of glucocorticoid receptor activity
Cedrol may help reduce liver fat and fat cell growth caused by corticosteroids.
research Clinical Snippets
Early sunburn treatment with certain inhibitors may reduce skin cancer risk.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
research ENDOXAN ALOPECIA
Endoxan often causes hair loss, which usually starts in the third week of treatment.
research Erosive pustular dermatosis of the scalp: a multicentre study
High-potency steroids or tacrolimus are effective treatments for Erosive Pustular Dermatosis of the Scalp.
research Transdermal permeation of tetracaine hydrochloride by lecithin microemulsion: In vivo
Lecithin microemulsion safely delivers tetracaine hydrochloride through the skin.
research ODAC Votes No on IntraDose Injectible Cisplatin/Epinephrine Gel for Head and Neck Cancer
The committee decided not to approve the drug due to low effectiveness and high risks.